My bibliography
Save this item
Market size and pharmaceutical innovation
Citations
Blog mentions
As found by EconAcademics.org, the blog aggregator for Economics research:- What’s at stake if U.S. drug prices fall?
by Jason Shafrin in Healthcare Economist on 2018-02-02 06:14:36
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Volker Grossmann, 2021. "Medical Innovations and Ageing: A Health Economics Perspective," CESifo Working Paper Series 9387, CESifo.
- Francesca Barigozzi & Izabela Jelovac, 2020.
"Research funding and price negotiation for new drugs,"
Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 83-96, October.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Working Papers 1901, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon.
- Francesca Barigozzi & Izabela Jelovac, 2020. "Research funding and price negotiation for new drugs," Post-Print halshs-02910863, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02148454, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02409768, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Working Papers halshs-01987643, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02148462, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02409743, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02409758, HAL.
- Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
- Dosi, Giovanni & Palagi, Elisa & Roventini, Andrea & Russo, Emanuele, 2023.
"Do patents really foster innovation in the pharmaceutical sector? Results from an evolutionary, agent-based model,"
Journal of Economic Behavior & Organization, Elsevier, vol. 212(C), pages 564-589.
- Giovanni Dosi & Elisa Palagi & Andrea Roventini & Emanuele Russo, 2021. "Do patents really foster innovation in the pharmaceutical sector? Results from an evolutionary, agent-based model," LEM Papers Series 2021/37, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
- Giovanni Dosi & Elisa Palagi & Andrea Roventini & Emanuele Russo, 2021. "Do patents really foster innovation in the pharmaceutical sector? Results from an evolutionary, agent-based model," SciencePo Working papers Main hal-04114900, HAL.
- Giovanni Dosi & Elisa Palagi & Andrea Roventini & Emanuele Russo, 2021. "Do patents really foster innovation in the pharmaceutical sector? Results from an evolutionary, agent-based model," Working Papers hal-04114900, HAL.
- Dranove, David & Garthwaite, Craig & Heard, Christopher & Wu, Bingxiao, 2022.
"The economics of medical procedure innovation,"
Journal of Health Economics, Elsevier, vol. 81(C).
- David Dranove & Craig Garthwaite & Christopher Heard & Bingxiao Wu, 2021. "The Economics of Medical Procedure Innovation," NBER Working Papers 29438, National Bureau of Economic Research, Inc.
- Heidi L. Williams, 2016.
"Intellectual Property Rights and Innovation: Evidence from Health Care Markets,"
Innovation Policy and the Economy, University of Chicago Press, vol. 16(1), pages 53-87.
- Heidi L. Williams, 2015. "Intellectual Property Rights and Innovation: Evidence from Health Care Markets," NBER Chapters, in: Innovation Policy and the Economy, Volume 16, pages 53-87, National Bureau of Economic Research, Inc.
- Heidi L. Williams, 2015. "Intellectual Property Rights and Innovation: Evidence from Health Care Markets," NBER Working Papers 21246, National Bureau of Economic Research, Inc.
- Javad Moradpour & Aidan Hollis, 2020. "Patient income and health innovation," Health Economics, John Wiley & Sons, Ltd., vol. 29(12), pages 1795-1803, December.
- Stern, Ariel Dora, 2017. "Innovation under regulatory uncertainty: Evidence from medical technology," Journal of Public Economics, Elsevier, vol. 145(C), pages 181-200.
- Frankovic, Ivan & Kuhn, Michael, 2023. "Health insurance, endogenous medical progress, health expenditure growth, and welfare," Journal of Health Economics, Elsevier, vol. 87(C).
- Pierre Dubois & Morten Sæthre, 2020.
"On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector,"
Econometrica, Econometric Society, vol. 88(6), pages 2503-2545, November.
- Dubois, Pierre & Sæthre, Morten, 2017. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," Discussion Paper Series in Economics 3/2018, Norwegian School of Economics, Department of Economics.
- Pierre Dubois & Morten Sæthre, 2020. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," Post-Print hal-03176406, HAL.
- Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," TSE Working Papers 18-883, Toulouse School of Economics (TSE), revised Mar 2020.
- Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector," CEPR Discussion Papers 12649, C.E.P.R. Discussion Papers.
- Kyle, Margaret, 2017. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," CEPR Discussion Papers 12420, C.E.P.R. Discussion Papers.
- Jeffrey Clemens, 2012.
"The Effect of U.S. Health Insurance Expansions on Medical Innovation,"
Discussion Papers
11-016, Stanford Institute for Economic Policy Research.
- Jeffrey Clemens, 2013. "The Effect of U.S. Health Insurance Expansions on Medical Innovation," NBER Working Papers 19761, National Bureau of Economic Research, Inc.
- Kalcheva, Ivalina & McLemore, Ping & Pant, Shagun, 2018. "Innovation: The interplay between demand-side shock and supply-side environment," Research Policy, Elsevier, vol. 47(2), pages 440-461.
- Frank, Richard G. & Zeckhauser, Richard J., 2018. "Excess Prices for Drugs in Medicare: Diagnosis and Prescription," Working Paper Series rwp18-005, Harvard University, John F. Kennedy School of Government.
- Dubois, Pierre & Moisson, Paul-Henri & Tirole, Jean, 2022. "The Economics of Transferable Patent Extensions," TSE Working Papers 22-1377, Toulouse School of Economics (TSE), revised Dec 2022.
- Dubois, Pierre & Gentry, Elissa & Tuncel, Tuba, 2023. "Strategic Submissions: A Cross-Country Analysis of Supplemental Drug Approvals," TSE Working Papers 23-1459, Toulouse School of Economics (TSE).
- Beerli, Andreas & Weiss, Franziska J. & Zilibotti, Fabrizio & Zweimüller, Josef, 2020.
"Demand forces of technical change evidence from the Chinese manufacturing industry,"
China Economic Review, Elsevier, vol. 60(C).
- Beerli, Andreas & Weiss, Franziska & Zilibotti, Fabrizio & Zweimüller, Josef, 2013. "Demand Forces of Technical Change Evidence from the Chinese Manufacturing Industry," VfS Annual Conference 2013 (Duesseldorf): Competition Policy and Regulation in a Global Economic Order 79980, Verein für Socialpolitik / German Economic Association.
- Andreas Beerli & Franziska J. Weiss & Fabrizio Zilibotti, 2018. "Demand forces of technical change: evidence from the Chinese manufacturing industry," ECON - Working Papers 277, Department of Economics - University of Zurich.
- Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2016.
"Patents and the Global Diffusion of New Drugs,"
American Economic Review, American Economic Association, vol. 106(1), pages 136-164, January.
- Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2014. "Patents and the Global Diffusion of New Drugs," NBER Working Papers 20492, National Bureau of Economic Research, Inc.
- Cockburn, Iain & Lanjouw, Jean O. & Schankerman, Mark, 2016. "Patents and the global diffusion of new drugs," LSE Research Online Documents on Economics 65415, London School of Economics and Political Science, LSE Library.
- Cockburn, Iain & Lanjouw, Jean O. & Schankerman, Mark, 2014. "Patents and the global diffusion of new drugs," LSE Research Online Documents on Economics 60450, London School of Economics and Political Science, LSE Library.
- Iain Cockburn & Jean O. Lanjouw & Mark Schankerman, 2014. "Patents and the Global Diffusion of New Drugs," CEP Discussion Papers dp1298, Centre for Economic Performance, LSE.
- Schankerman, Mark & Cockburn, Iain M & Lanjouw, Jean, 2014. "Patents and the Global Diffusion of New Drugs," CEPR Discussion Papers 10149, C.E.P.R. Discussion Papers.
- Mujaheed Shaikh & Pietro Giudice & Dimitrios Kourouklis, 2021.
"Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment,"
Applied Health Economics and Health Policy, Springer, vol. 19(2), pages 217-229, March.
- Mujaheed Shaikh & Pietro del Giudice & Dimitrios Kourouklis, 2020. "Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment," Post-Print hal-03046856, HAL.
- Agarwal, Ruchir & Gaule, Patrick, 2022.
"What drives innovation? Lessons from COVID-19 R&D,"
Journal of Health Economics, Elsevier, vol. 82(C).
- Agarwal, Ruchir & Gaule, Patrick, 2021. "What Drives Innovation? Lessons from COVID-19 R&D," IZA Discussion Papers 14079, Institute of Labor Economics (IZA).
- Ruchir Agarwal & Patrick Gaulé, 2021. "What Drives Innovation? Lessons from COVID-19 R&D," IMF Working Papers 2021/048, International Monetary Fund.
- Kazuhiro Takauchi & Tomomichi Mizuno, 2019.
"Consumer-benefiting transport cost: The role of product innovation in a vertical structure,"
Discussion Papers
1911, Graduate School of Economics, Kobe University.
- Kazuhiro Takauchi & Tomomichi Mizuno, 2020. "Consumer-benefiting transport cost: The role of product innovation in a vertical structure," Discussion Papers 2017, Graduate School of Economics, Kobe University.
- Iizuka, Toshiaki & Uchida, Gyo, 2017.
"Promoting innovation in small markets: Evidence from the market for rare and intractable diseases,"
Journal of Health Economics, Elsevier, vol. 54(C), pages 56-65.
- IIZUKA Toshiaki & UCHIDA Gyo, 2016. "Promoting Innovation in Small Markets: Evidence from the market for rare and intractable diseases," Discussion papers 16036, Research Institute of Economy, Trade and Industry (RIETI).
- Jeffrey P. Clemens & Morten Olsen, 2021. "Medicare and the Rise of American Medical Patenting: The Economics of User-Driven Innovation," CESifo Working Paper Series 9008, CESifo.
- Simona Gamba & Laura Magazzini & Paolo Pertile, 2019. "R&D and market size: who benefits from orphan drug regulation?," Working Papers 09/2019, University of Verona, Department of Economics.
- Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
- Schwardmann, Peter, 2019.
"Motivated health risk denial and preventative health care investments,"
Journal of Health Economics, Elsevier, vol. 65(C), pages 78-92.
- Schwardmann, Peter, 2017. "Motivated Health Risk Denial and Preventative Health Care Investments," Rationality and Competition Discussion Paper Series 33, CRC TRR 190 Rationality and Competition.
- Barton H. Hamilton & Andrés Hincapié & Robert A. Miller & Nicholas W. Papageorge, 2021.
"Innovation And Diffusion Of Medical Treatment,"
International Economic Review, Department of Economics, University of Pennsylvania and Osaka University Institute of Social and Economic Research Association, vol. 62(3), pages 953-1009, August.
- Barton H. Hamilton & Andrés Hincapié & Robert A. Miller & Nicholas W. Papageorge, 2018. "Innovation and Diffusion of Medical Treatment," NBER Working Papers 24577, National Bureau of Economic Research, Inc.
- Yan Wen & Lu Liu, 2023. "Comparative Study on Low-Carbon Strategy and Government Subsidy Model of Pharmaceutical Supply Chain," Sustainability, MDPI, vol. 15(10), pages 1-26, May.
- Jillian Chown & David Dranove & Craig Garthwaite & Jordan Keener, 2019. "The Opportunities and Limitations of Monopsony Power in Healthcare: Evidence from the United States and Canada," NBER Working Papers 26122, National Bureau of Economic Research, Inc.
- Arzi Adbi & Chirantan Chatterjee & Matej Drev & Anant Mishra, 2019. "When the Big One Came: A Natural Experiment on Demand Shock and Market Structure in India's Influenza Vaccine Markets," Production and Operations Management, Production and Operations Management Society, vol. 28(4), pages 810-832, April.
- Lemarié, Stéphane & Parenty, Sébastien, 2016. "Research incentives and tradeoff for improving productivity of different crops," 149th Seminar, October 27-28, 2016, Rennes, France 245161, European Association of Agricultural Economists.
- Javad Moradpour & Aidan Hollis, 2021. "The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 1139-1151, May.
- Ugur, Mehmet & Trushin, Eshref, 2018. "Asymmetric information and heterogeneous effects of R&D subsidies: evidence on R&D investment and employment of R&D personel," Greenwich Papers in Political Economy 21943, University of Greenwich, Greenwich Political Economy Research Centre.
- Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).
- Felipa de Mello-Sampayo & Sofia de Sousa-Vale & Francisco Camoes, 2015. "Substitutability Between Drugs, Innovation, and Fiscal Policy in the Pharmaceutical Industry," Annals of Economics and Finance, Society for AEF, vol. 16(2), pages 273-289, November.
- Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022. "Generic competition and the incentives for early-stage pharmaceutical innovation," Research Policy, Elsevier, vol. 51(10).
- Federico Nutarelli & Massimo Riccaboni & Andrea Morescalchi, 2021. "Product recalls, market size and innovation in the pharmaceutical industry," Papers 2111.15389, arXiv.org.
- Massimo Florio & Simona Gamba, 2021.
"Biomed Europa: After the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly,"
Annals of Public and Cooperative Economics, Wiley Blackwell, vol. 92(3), pages 387-409, September.
- Massimo FLORIO, 2020. "Biomed Europa: after the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly," CIRIEC Working Papers 2008, CIRIEC - Université de Liège.
- Aggarwal, Mayank & Chakrabarti, Anindya S. & Chatterjee, Chirantan & Higgins, Matthew J., 2023. "Research and market structure: Evidence from an antibiotic-resistant pathogenic outbreak," Research Policy, Elsevier, vol. 52(1).
- Dubois, Pierre & Majewska, Gosia, 2022.
"Mergers and Advertising in the Pharmaceutical Industry,"
CEPR Discussion Papers
17658, C.E.P.R. Discussion Papers.
- Dubois, Pierre & Majewska, Gosia, 2022. "Mergers and Advertising in the Pharmaceutical Industry," TSE Working Papers 22-1380, Toulouse School of Economics (TSE).
- Johnson, Abbie-Gayle & Buhalis, Dimitrios, 2022. "Solidarity during times of crisis through co-creation," Annals of Tourism Research, Elsevier, vol. 97(C).
- Asher Curtis & Sarah McVay & Sara Toynbee, 2020. "The changing implications of research and development expenditures for future profitability," Review of Accounting Studies, Springer, vol. 25(2), pages 405-437, June.
- Zhang, Xuan & Nie, Huihua, 2021. "Public health insurance and pharmaceutical innovation: Evidence from China," Journal of Development Economics, Elsevier, vol. 148(C).
- Mehmet Ugur & Eshref Trushin, 2023.
"Information asymmetry, risk aversion and R&D subsidies: effect-size heterogeneity and policy conundrums,"
Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 32(8), pages 1190-1215, November.
- Ugur, Mehmet & Trushin, Eshref, 2021. "Information asymmetry, risk aversion and R&D subsidies: Effect-size heterogeneity and policy conundrums," Greenwich Papers in Political Economy 32224, University of Greenwich, Greenwich Political Economy Research Centre.
- Jeffrey Clemens & Parker Rogers, 2020.
"Demand Shocks, Procurement Policies, and the Nature of Medical Innovation: Evidence from Wartime Prosthetic Device Patents,"
NBER Working Papers
26679, National Bureau of Economic Research, Inc.
- Jeffrey P. Clemens & Parker Rogers, 2020. "Demand Shocks, Procurement Policies, and the Nature of Medical Innovation: Evidence from Wartime Prosthetic Device Patents," CESifo Working Paper Series 8781, CESifo.
- Marek Ignaszak & Petr Sedlácek, 2021.
"Profitability, Productivity and Growth,"
Economics Series Working Papers
937, University of Oxford, Department of Economics.
- Marek Ignaszak & Petr Sedlacek, 2021. "Profitability, Productivity and Growth," Discussion Papers 2115, Centre for Macroeconomics (CFM).
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022.
"Bargaining and International Reference Pricing in the Pharmaceutical Industry,"
Research Papers
3889, Stanford University, Graduate School of Business.
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," TSE Working Papers 22-1338, Toulouse School of Economics (TSE).
- Pierre Dubois & Ashvin Gandhi & Shoshana Vasserman, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," NBER Working Papers 30053, National Bureau of Economic Research, Inc.
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," CEPR Discussion Papers 17293, C.E.P.R. Discussion Papers.
- Fabian Gaessler & Stefan Wagner, 2022.
"Patents, Data Exclusivity, and the Development of New Drugs,"
The Review of Economics and Statistics, MIT Press, vol. 104(3), pages 571-586, May.
- Gaessler, Fabian & Wagner, Stefan, 2019. "Patents, Data Exclusivity, and the Development of New Drugs," Rationality and Competition Discussion Paper Series 176, CRC TRR 190 Rationality and Competition.
- Mark Pauly & Kyle Myers, 2016. "A Ricardian-Demand Explanation for Changing Pharmaceutical R&D Productivity," NBER Working Papers 22720, National Bureau of Economic Research, Inc.
- Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
- Wang, Lucy Xiaolu, 2022. "Global drug diffusion and innovation with the medicines patent pool," Journal of Health Economics, Elsevier, vol. 85(C).
- Sahm, Marco, 2016. "Advance-purchase financing of projects with few buyers," BERG Working Paper Series 118, Bamberg University, Bamberg Economic Research Group.
- Blume-Kohout, Margaret E. & Sood, Neeraj, 2013. "Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development," Journal of Public Economics, Elsevier, vol. 97(C), pages 327-336.
- Kortelainen, Mika & Markkanen, Jaakko & Siikanen, Markku & Toivanen, Otto, 2023. "The Effects of Price Regulation on Pharmaceutical Expenditure and Availability," Working Papers 157, VATT Institute for Economic Research.
- Manuel Hermosilla, 2021. "Rushed Innovation: Evidence from Drug Licensing," Management Science, INFORMS, vol. 67(1), pages 257-278, January.
- Fiona M. Scott Morton & Ariel Dora Stern & Scott Stern, 2018. "The Impact of the Entry of Biosimilars: Evidence from Europe," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 173-210, August.
- Dubois, Pierre & Majewska, Gosia & Reig, Valentina, 2023. "Drug Shortages: Empirical Evidence from France," TSE Working Papers 23-1417, Toulouse School of Economics (TSE).
- Yong Tan, 2019. "Dynamic Entry With Demand And Supply Side Spillovers," Contemporary Economic Policy, Western Economic Association International, vol. 37(1), pages 86-101, January.
- Amitabh Chandra & Craig Garthwaite & Ariel Dora Stern, 2018.
"Characterizing the Drug Development Pipeline for Precision Medicines,"
NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 115-157,
National Bureau of Economic Research, Inc.
- Amitabh Chandra & Craig Garthwaite & Ariel Dora Stern, 2017. "Characterizing the Drug Development Pipeline for Precision Medicines," NBER Working Papers 24026, National Bureau of Economic Research, Inc.
- Margaret K. Kyle, 2018. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 211-234, August.
- Branstetter, Lee G. & Kwon, Namho, 2018. "South Korea's transition from imitator to innovator: The role of external demand shocks," Journal of the Japanese and International Economies, Elsevier, vol. 49(C), pages 28-42.
- Eric Budish & Benjamin N. Roin & Heidi Williams, 2015.
"Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials,"
American Economic Review, American Economic Association, vol. 105(7), pages 2044-2085, July.
- Eric Budish & Benjamin N. Roin & Heidi Williams, 2013. "Do firms underinvest in long-term research? Evidence from cancer clinical trials," NBER Working Papers 19430, National Bureau of Economic Research, Inc.
- Anna Chorniy & James Bailey & Abdulkadir Civan & Michael Maloney, 2021. "Regulatory review time and pharmaceutical research and development," Health Economics, John Wiley & Sons, Ltd., vol. 30(1), pages 113-128, January.
- Matthew J. Higgins & Mathias J. Kronlund & Ji Min Park & Joshua Pollet, 2020. "The Role of Assets In Place: Loss of Market Exclusivity and Investment," NBER Working Papers 27588, National Bureau of Economic Research, Inc.
- Huvaj, M. Nesij & Johnson, William C., 2019. "Organizational complexity and innovation portfolio decisions: Evidence from a quasi-natural experiment," Journal of Business Research, Elsevier, vol. 98(C), pages 153-165.
- Liu, Qing & Ma, Hong, 2020. "Trade policy uncertainty and innovation: Firm level evidence from China’s WTO accession," Journal of International Economics, Elsevier, vol. 127(C).
- Marco Sahm, 2020. "Advance-Purchase Financing of Projects with Few Buyers," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 57(4), pages 909-933, December.
- Wei Fu & Shin-Yi Chou & Li-San Wang, 2022. "NIH Grant Expansion, Ancestral Diversity and Scientific Discovery in Genomics Research," NBER Working Papers 30155, National Bureau of Economic Research, Inc.
- Leila Agha & Soomi Kim & Danielle Li, 2020. "Insurance Design and Pharmaceutical Innovation," NBER Working Papers 27563, National Bureau of Economic Research, Inc.
- Callejas, Jerónimo & Mohapatra, Debi Prasad, 2021. "Welfare effects of public procurement of medicines: Evidence from Ecuador," International Journal of Industrial Organization, Elsevier, vol. 75(C).
- Civelek Mehmet & Červinka Michal & Gajdka Krzysztof & Nétek Václav, 2021. "Marketing communication tools and their influence on marketing innovation: Evidence from Slovakian SMEs," Management & Marketing, Sciendo, vol. 16(3), pages 210-227, September.
- Dubois, P.; & Majewska, G.; & Reig, V.;, 2023. "Drug Shortages: Empirical Evidence from France," Health, Econometrics and Data Group (HEDG) Working Papers 23/07, HEDG, c/o Department of Economics, University of York.
- Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
- David Dranove & Craig Garthwaite & Manuel Hermosilla, 2014. "Pharmaceutical Profits and the Social Value of Innovation," NBER Working Papers 20212, National Bureau of Economic Research, Inc.
- Higgins, Matthew J. & Yan, Xin & Chatterjee, Chirantan, 2021. "Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling," Research Policy, Elsevier, vol. 50(1).
- Hermosilla, Manuel & Wu, Yufei, 2018. "Market size and innovation: The intermediary role of technology licensing," Research Policy, Elsevier, vol. 47(5), pages 980-991.